Thiard News@F4F

@newsen.bsky.social

1 day ago

Bambusa Therapeutics Showcases Promising Trial Outcomes for BBT001 at AAD 2026 Bambusa Therapeutics presented impressive Phase 1 trial results for BBT001 at the AAD 2026 Annual Meeting, demonstrating its potential for treating atopic dermatitis.

Bambusa Therapeutics Showcases Promising Trial Outcomes for BBT001 at AAD 2026 #United_States #Denver #Atopic_Dermatitis #Bambusa_Therapeutics #BBT001

Thiard News@F4F

@newsen.bsky.social

6 days ago

Lilly's EBGLYSS Shows Four Years of Lasting Control for Eczema Patients Eli Lilly's EBGLYSS has demonstrated impressive long-term efficacy and safety in treating moderate-to-severe atopic dermatitis, providing significant skin improvement and itch relief for up to four years.

Lilly's EBGLYSS Shows Four Years of Lasting Control for Eczema Patients #United_States #Indianapolis #Atopic_Dermatitis #Eli_Lilly #EBGLYSS

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Eli Lilly's EBGLYSS Shows Promising Results for Young Patients with Atopic Dermatitis Eli Lilly's EBGLYSS emerges as the first selective IL-13 inhibitor with positive Phase 3 results for children aged six months to 18 years suffering from moderate-to-severe atopic dermatitis, showcasing significant skin improvement.

Eli Lilly's EBGLYSS Shows Promising Results for Young Patients with Atopic Dermatitis #USA #Indianapolis #Atopic_Dermatitis #Eli_Lilly #EBGLYSS

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Alphyn Biologics Completes Enrollment for Groundbreaking Atopic Dermatitis Clinical Trial Alphyn Biologics has successfully enrolled participants in the pivotal CLEAR-AD1 trial for its innovative atopic dermatitis treatment, Zabalafin Hydrogel.

Alphyn Biologics Completes Enrollment for Groundbreaking Atopic Dermatitis Clinical Trial #United_States #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

1 month ago

Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis Lynk Pharmaceuticals has announced promising topline results from its Phase III trial of zemprocitinib, aimed at treating moderate-to-severe atopic dermatitis, demonstrating significant efficacy and safety.

Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis #China #Shanghai #Atopic_Dermatitis #Lynk_Pharmaceuticals #Zemprocitinib

Thiard News@F4F

@newsen.bsky.social

1 month ago

Rezpegaldesleukin Shows Promising Long-term Responses in Atopic Dermatitis Patients New data on rezpegaldesleukin reveals promising long-term efficacy and safety for atopic dermatitis, demonstrating significant patient responses and disease control.

Rezpegaldesleukin Shows Promising Long-term Responses in Atopic Dermatitis Patients #United_States #San_Francisco #Atopic_Dermatitis #Nektar_Therapeutics #Rezpegaldesleukin

Thiard News@F4F

@newsen.bsky.social

3 months ago

Alphyn Biologics Secures $25 Million to Enhance Its Dermatology Pipeline and Target Atopic Dermatitis Alphyn Biologics has successfully closed a $25 million Series B funding round for advancing clinical trials of its innovative dermatology therapies, aiming to combat atopic dermatitis and molluscum contagiosum.

Alphyn Biologics Secures $25 Million to Enhance Its Dermatology Pipeline and Target Atopic Dermatitis #United_States #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

3 months ago

Sibel Health Receives $500,000 Grant for Innovative AI-Driven Wearable Sensor in Dermatology Sibel Health has been awarded a $500,000 FDA grant to develop an AI-enabled wearable sensor for scratching behavior assessment in atopic dermatitis.

Sibel Health Receives $500,000 Grant for Innovative AI-Driven Wearable Sensor in Dermatology #USA #Chicago #Atopic_Dermatitis #Sibel_Health #ADAM_Sensor

Thiard News@F4F

@newsen.bsky.social

4 months ago

ixlayer Launches SkinLink to Enhance Access to Dermatological Care Across the Nation ixlayer introduces SkinLink.us, a platform connecting patients with dermatologists for expert care in managing chronic skin conditions like Atopic Dermatitis.

ixlayer Launches SkinLink to Enhance Access to Dermatological Care Across the Nation #USA #San_Francisco #Atopic_Dermatitis #ixlayer #SkinLink

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lynk Pharmaceuticals Reveals Promising Phase II Results for LNK01004 in Atopic Dermatitis Treatment Lynk Pharmaceuticals has announced promising results from Phase II clinical trials of LNK01004, a treatment for atopic dermatitis, showcasing both efficacy and safety.

Lynk Pharmaceuticals Reveals Promising Phase II Results for LNK01004 in Atopic Dermatitis Treatment #China #Hangzhou #Atopic_Dermatitis #Lynk_Pharmaceuticals #LNK01004

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Mutant IL-2 Fusion Protein SIM0278 Enters Phase II Clinical Trials Simcere Pharmaceutical Group announces the advancement of SIM0278, a mutant IL-2 fusion protein, into Phase II clinical trials targeting moderate to severe atopic dermatitis.

Simcere's Mutant IL-2 Fusion Protein SIM0278 Enters Phase II Clinical Trials #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials Simcere Pharmaceutical Group has announced that its mutant IL-2 fusion protein, SIM0278, has entered Phase II clinical trials for the treatment of moderate to severe atopic dermatitis.

Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Innovative IL-2 Mutant Fusion Protein Enters Phase II Trials to Combat Atopic Dermatitis Simcere Pharmaceutical’s IL-2 mu-Fc, SIM0278, has entered Phase II clinical trials in China for treating moderate-to-severe atopic dermatitis, offering new hope to patients.

Simcere's Innovative IL-2 Mutant Fusion Protein Enters Phase II Trials to Combat Atopic Dermatitis #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

5 months ago

Concerto Biosciences Reports Promising Results for ENS-002 in Atopic Dermatitis Trials Concerto Biosciences unveils encouraging Phase 1b trial results for ENS-002, a new topical treatment for atopic dermatitis, showcasing safety and efficacy.

Concerto Biosciences Reports Promising Results for ENS-002 in Atopic Dermatitis Trials #USA #Cambridge #Atopic_Dermatitis #Concerto_Biosciences #ENS-002

Thiard News@F4F

@newsen.bsky.social

5 months ago

Alphyn Biologics Secures New Patent for Innovative Atopic Dermatitis Treatment Alphyn Biologics has expanded its patent portfolio with a game-changing U.S. patent, supporting its new therapeutic for atopic dermatitis.

Alphyn Biologics Secures New Patent for Innovative Atopic Dermatitis Treatment #USA #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lilly's EBGLYSS Shows Encouraging Long-Term Control for Atopic Dermatitis Treatment Eli Lilly's EBGLYSS effectively maintains skin improvement in eczema patients with a less frequent dosing schedule, providing an innovative treatment option.

Lilly's EBGLYSS Shows Encouraging Long-Term Control for Atopic Dermatitis Treatment #United_States #Indianapolis #Atopic_Dermatitis #EBGLYSS #lebrikizumab

Thiard News@F4F

@newsen.bsky.social

6 months ago

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research Discover how SciBase's Nevisense is advancing skin barrier research in atopic dermatitis, enhancing diagnostic methods and treatment monitoring.

SciBase's Nevisense: A Revolutionary Tool in Atopic Dermatitis Skin Barrier Research #Sweden #Stockholm #Atopic_Dermatitis #Nevisense #SciBase

Thiard News@F4F

@newsen.bsky.social

6 months ago

Bambusa Therapeutics Reports Positive Phase I Results for BBT001 in Atopic Dermatitis Trials Bambusa Therapeutics has announced impressive Phase I trial results for its BBT001 antibody aimed at treating atopic dermatitis, marking a significant milestone.

Bambusa Therapeutics Reports Positive Phase I Results for BBT001 in Atopic Dermatitis Trials #USA #Boston #Atopic_Dermatitis #Bambusa_Therapeutics #BBT001

Thiard News@F4F

@newsen.bsky.social

6 months ago

Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment Triveni Bio has begun a crucial Phase 2 clinical trial for TRIV-509, targeting atopic dermatitis, showcasing advancements in antibody treatments.

Triveni Bio Initiates Phase 2 Trial of TRIV-509 for Atopic Dermatitis Treatment #USA #Atopic_Dermatitis #Watertown #Triveni_Bio #TRIV-509

Thiard News@F4F

@newsen.bsky.social

6 months ago

EADV Congress 2025 Highlights: Atopic Dermatitis Linked to Increased Suicidal Thoughts A groundbreaking study presented at the EADV Congress 2025 reveals a startling link between atopic dermatitis and suicidal thoughts in adults, stressing the need for mental health awareness.

EADV Congress 2025 Highlights: Atopic Dermatitis Linked to Increased Suicidal Thoughts #Paris #France #mental_health #Atopic_Dermatitis #EADV_Congress_2025

Thiard News@F4F

@newsen.bsky.social

6 months ago

CAGE Bio's Phase 2b Trial Shows Promising Results for Atopic Dermatitis Treatment CAGE Bio announces significant results from its Phase 2b trial of CGB-500, showing high effectiveness in treating atopic dermatitis with a favorable safety profile.

CAGE Bio's Phase 2b Trial Shows Promising Results for Atopic Dermatitis Treatment #United_States #Atopic_Dermatitis #San_Carlos #CAGE_Bio #CGB-500

Thiard News@F4F

@newsen.bsky.social

8 months ago

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress Kyowa Kirin is set to present the Phase 3 trial results of Rocatinlimab, a promising therapy for atopic dermatitis, at the EADV congress in Paris.

Kyowa Kirin to Present Important Findings on Rocatinlimab at EADV 2025 Congress #Japan #Tokyo #Atopic_Dermatitis #Kyowa_Kirin #Rocatinlimab

Thiard News@F4F

@newsen.bsky.social

9 months ago

Alphyn Biologics' Zabalafin Hydrogel: A Breakthrough in Atopic Dermatitis Treatment Alphyn Biologics announces the publication of significant findings regarding Zabalafin Hydrogel, a novel treatment for atopic dermatitis now spotlighted in a major peer-reviewed journal.

Alphyn Biologics' Zabalafin Hydrogel: A Breakthrough in Atopic Dermatitis Treatment #United_States #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

10 months ago

Alphyn Initiates Global Phase 2b Clinical Study on Atopic Dermatitis Treatment CLEAR-AD1 Alphyn GmbH has launched a Phase 2b study on Zabalafin Hydrogel, aimed at addressing atopic dermatitis effectively. The first patients have been treated in Australia.

Alphyn Initiates Global Phase 2b Clinical Study on Atopic Dermatitis Treatment CLEAR-AD1 #USA #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

10 months ago

Alphyn Starts Global Phase 2b CLEAR-AD1 Clinical Trials for Atopic Dermatitis Alphyn GmbH has launched the CLEAR-AD1 Phase 2b clinical trial for its innovative treatment, Zabalafin Hydrogel, aimed at tackling atopic dermatitis effectively.

Alphyn Starts Global Phase 2b CLEAR-AD1 Clinical Trials for Atopic Dermatitis #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

11 months ago

Galderma Introduces Campaign to Address the Hidden Struggles of Atopic Dermatitis Galderma's 'Scratch Resistance' campaign sheds light on the emotional and physical effects of atopic dermatitis, encouraging treatment options for those affected.

Galderma Introduces Campaign to Address the Hidden Struggles of Atopic Dermatitis #USA #Boston #Atopic_Dermatitis #Galderma #NEMLUVIO

Thiard News@F4F

@newsen.bsky.social

11 months ago

Alphyn Unveils First Patient Dosed in Groundbreaking Atopic Dermatitis Trial for Zabalafin Hydrogel Alphyn has initiated its Phase 2b clinical trial for Zabalafin Hydrogel, targeting atopic dermatitis, marking a milestone in innovative dermatological treatments.

Alphyn Unveils First Patient Dosed in Groundbreaking Atopic Dermatitis Trial for Zabalafin Hydrogel #United_States #Annapolis #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

1 year ago

Evommune's Innovative Phase 2 Trial for EVO301 Tackles Atopic Dermatitis Challenges Evommune has initiated a pivotal Phase 2 clinical trial for EVO301, a targeted therapy for adult patients suffering from atopic dermatitis. This innovative treatment aims to address unmet needs in effective dermatological care.

Evommune's Innovative Phase 2 Trial for EVO301 Tackles Atopic Dermatitis Challenges #United_States #Palo_Alto #Atopic_Dermatitis #Evommune #EVO301

Thiard News@F4F

@newsen.bsky.social

1 year ago

Alphyn Unveils Zabalafin Hydrogel at AAD Meeting as a Revolutionary Atopic Dermatitis Treatment Alphyn's Zabalafin Hydrogel presents groundbreaking results in atopic dermatitis management, promising a comprehensive, safe treatment approach.

Alphyn Unveils Zabalafin Hydrogel at AAD Meeting as a Revolutionary Atopic Dermatitis Treatment #United_States #Orlando #Atopic_Dermatitis #Zabalafin_Hydrogel #Alphyn_Biologics

Thiard News@F4F

@newsen.bsky.social

1 year ago

Breakthrough Results of EBGLYSS® Therapy for Atopic Dermatitis Demonstrated at AAD Annual Meeting Eli Lilly's EBGLYSS® therapy shows promising results for atopic dermatitis with long-term skin clearance and symptom relief in numerous patients.

Breakthrough Results of EBGLYSS® Therapy for Atopic Dermatitis Demonstrated at AAD Annual Meeting #United_States #Indianapolis #Atopic_Dermatitis #Eli_Lilly #EBGLYSS